Director James Huang Buys $371K in Open Market Shares
CNTB has more than doubled off its 52-week low of $0.73.
Summary
Director James Huang made an open market purchase of $371,610 worth of Connect Biopharma ordinary shares, continuing a trend of insider accumulation.
Key Events · Ownership and Investor Activity · CNTB
-
Director Open Market Purchase
Director James Huang acquired 150,000 ordinary shares for $371,610 at a weighted average price of $2.48 per share on May 29, 2026.
-
Continued Insider Accumulation
This purchase follows a larger $4.0 million acquisition by Director Huang in early April, indicating sustained insider belief in the company's prospects.
-
Post-Transaction Holdings
Following this transaction, James Huang's indirect holdings total 13,310,000 shares.
Analysis · CNTB · Life Sciences
This open market purchase by Director James Huang, following a larger $4.0 million acquisition in early April, indicates continued insider confidence in Connect Biopharma. The transaction occurred after recent positive Phase 3 trial results and a significant private placement, suggesting the director sees further upside despite the company's recent financial performance.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTB was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $135.4M. The 52-week trading range was $0.73 to $3.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.